Dynavax (DVAX) Presents Data from SD-101 + Keytruda Phase 1/2 in Metastatic Melanoma; One CR Noted
Tweet Send to a Friend
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101, Dynavax's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
